Skip to content

ScienceChai Discovery

Chai Discovery

Foundation models for molecular structure and antibody design.

Category
Science
Pricing
FREEMIUM
Source
Open core
Hosting
Cloud
Platforms
WebAPI
Verified
Jun 14, 2026

Chai Discovery builds foundation models for drug discovery — Chai-1 for biomolecular structure prediction across proteins, ligands, DNA/RNA, and glycans, and Chai-2 for de novo antibody design. Chai-1 weights and inference code are released for non-commercial use, and a free web server runs the model in-browser. It is both a model provider and a usable platform.

Pros & cons

  • Free in-browser structure prediction
  • Open Chai-1 weights
  • SOTA protein-ligand accuracy
  • OpenAI-backed
  • Weights non-commercial only
  • Chai-2 not open
  • Young company (2024)
  • Core IP still proprietary

Tags

Further reading

View all Science
  • View EvolutionaryScale details
    ScienceFREEMIUMOpen core

    EvolutionaryScale

    EvolutionaryScale

    Frontier protein language models (the ESM family) for biology.

    EvolutionaryScale builds frontier protein language models — the ESM family, including ESM3, which reasons jointly over sequence, structure, and function. ESM3-open ships open weights and code under a non-commercial license, while larger models are served via its Forge API and AWS/NVIDIA partnerships. It is both an open-model provider and an API platform for protein design and understanding.

    Worth knowing

    Founded in 2023 by ex-Meta FAIR scientists after Meta cut its protein team; launched ESM3 with a $142M seed round.

    • protein-language-model
    • esm3
    • biotech
    • open-weights
  • View Profluent details
    SciencePAID

    Profluent

    Profluent Bio

    Generative protein language models that design novel proteins.

    Profluent uses generative AI — its ProGen-lineage protein language models — to author novel proteins from scratch or from natural scaffolds, for medicine and agriculture. It released OpenCRISPR-1, described as the first AI-designed gene editor (open-licensed and published in Nature), and is expanding into antibodies and enzymes. It operates as an AI protein-design company working through partnerships with open-sequence releases, not a self-serve consumer platform.

    Worth knowing

    Spun out of a Salesforce-funded ProGen project; open-released OpenCRISPR-1, billed as the first AI-designed gene editor.

    • protein-design
    • gene-editing
    • drug-discovery
    • biotech
  • View Isomorphic Labs details
    SciencePAID

    Isomorphic Labs

    Isomorphic Labs

    AI-first drug design built on AlphaFold for pharma R&D.

    Isomorphic Labs is an AI-first drug discovery company spun out of Google DeepMind, building generative and predictive ML models for molecular design and drug-performance prediction. Its Drug Design Engine builds on AlphaFold to advance internal and partnered pipelines with Eli Lilly, Novartis, and J&J. It is a drug-discovery company that works through pharma R&D partnerships rather than a self-serve product.

    Worth knowing

    DeepMind spinout (2021); raised a $600M Series A led by Thrive Capital with Alphabet and GV in March 2025 — its first external capital.

    • drug-discovery
    • alphafold
    • protein
    • biotech